Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Lapatinib-induced liver injury characterized by class II HLA and Gilbert's syndrome genotypes.

Clinical pharmacology and therapeutics - 1 Apr 2012

Spraggs C F, Parham L R, Hunt C M, Dollery C T

Abstract excerpt

Lapatinib is a clinically important component of the treatment for HER2-positive metastatic breast cancer and has an acceptable safety profile. Lapatinib-associated Hy's Law cases have been characterized using human leukocyte antigen (HLA) DQA1*02:01/DRB1*07:01 and Gilbert's syndrome UGT1A1*28/*28 genotypes. The HLA-positive cases had higher alanine aminotransferase (ALT) elevation, whereas the HLA-negative cases...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alanine Transaminase
Share to Chemical and Drug Induced Liver Injury

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gilbert Disease

Share to Glucuronosyltransferase

Share to HLA-DQ alpha-Chains

Share to HLA-DRB1 Chains

Share to Lapatinib

Share to Quinazolines

Source

Identifiers

PMID: 22357454
DOI: 10.1038/clpt.2011.277

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Lapatinib-induced liver injury characterized by class II HLA and Gilbert's syndrome genotypes.PMID 22357454Read ↗

Comprehensive genome-wide evaluation of lapatinib-induced liver injury yields a single genetic signal centered on known risk allele HLA-DRB1*07:01.Semantic proximity Read ↗

HLA-DQA1*02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer.Semantic proximity Read ↗

Genetic Characterization to Improve Interpretation and Clinical Management of Hepatotoxicity Caused by Tyrosine Kinase InhibitorsSemantic proximity Read ↗

Prospective validation of HLA-DRB1*07:01 allele carriage as a predictive risk factor for lapatinib-induced liver injury.Semantic proximity Read ↗

Characterisation of the HLA-DRB1*07:01 biomarker for lapatinib-induced liver toxicity during treatment of early-stage breast cancer patients with lapatinib in combination with trastuzumab and/or taxanes.Semantic proximity Read ↗

In silicoanalysis of HLA associations with drug-induced liver injury: use of a HLA-genotyped DNA archive from healthy volunteersSemantic proximity Read ↗

Rash in lapatinib-treated patients is not associated with human leukocyte antigen polymorphisms.Semantic proximity Read ↗

Gilbert-Meulengracht's syndrome and pharmacogenetics: is jaundice just the tip of the iceberg?Semantic proximity Read ↗

A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury.Semantic proximity Read ↗

HLA class II genotype influences the type of liver injury in drug-induced idiosyncratic liver disease.Semantic proximity Read ↗

LAPTM4B allele *2 is a marker of poor prognosis following hepatic tumor resection for hepatocellular carcinoma.Semantic proximity Read ↗

Nilotinib-induced liver injury: A case report.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.